CN101766626A - Blonanserin-contained oral preparation for treating schizophrenia - Google Patents
Blonanserin-contained oral preparation for treating schizophrenia Download PDFInfo
- Publication number
- CN101766626A CN101766626A CN200810154638A CN200810154638A CN101766626A CN 101766626 A CN101766626 A CN 101766626A CN 200810154638 A CN200810154638 A CN 200810154638A CN 200810154638 A CN200810154638 A CN 200810154638A CN 101766626 A CN101766626 A CN 101766626A
- Authority
- CN
- China
- Prior art keywords
- preparation
- agent
- piperazinyl
- fluorophenyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Disclosed is a Blonanserin-contained oral preparation for treating schizophrenia, using a 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-cycloocta[b]pyridine as ingredient, and one or more pharmaceutically acceptable excipients. The preparation method comprises the steps of mixing the 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-cycloocta[b]pyridine and the alternative thinner, adhesive, disintegrant, abhesive and lubricant with an appropriate amount of humectants to prepare soft wood, sieving to prepare wet granules, drying the wet granules, sieving and integrating the granules to prepare oral preparation, wherein, the Blonanserin is 0.1-30 per cent of the preparation by weight. The preparation is applicable to administrate 1-2 times per day in 1-2 preparation units each time, and used for controlling the concentration of the 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-cycloocta[b]pyridine in the plasma of human body, thus enabling the 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-cycloocta[b]pyridine to play a role in treatment.
Description
Technical field
The present invention relates to technical field of medicine, relate in particular to and contain 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9, oral formulations of 10-six hydrogen cycloocta-[b] pyridines and preparation method thereof.Take said preparation and make 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9 in the human plasma, 10-six hydrogen cycloocta-[b] pyridines maintain treatment level.
Background technology
Schizophrenia is a kind of disease that is split into feature with the cognitive power and the emotion degree of depth, shows as the most basic behavior of men and is affected, for example language, thought, consciousness and self-perception etc.The included scope of the symptom of this disease is wider, and modal is the obstacle of spiritual aspect, such as hallucinate, paranoea and illusion etc.
According to statistics, the prevalence rate of schizophrenia in the whole world is 0.5%～1.5%, and has only 5% finally can be returned to one's perfect health in the patient that all are received treatment.In addition; because schizophrenia can cause complication usually; for example anxiety disorder, depression or mental drug abuse etc.; show according to one of Datamonitor investigation, surpass the puzzlement that 1/3 (38%) schizophrenic will suffer at least one or diseases such as multinomial concurrent psychosis or cognitive disorder.Therefore, TB Ustun in 1999 in an investigation statistics that carries out at the global burden of mental disorder, classify schizophrenia as global the third-largest disabling condition, its rank forward even surpassed hemiplegia and blind, from then on, the schizophrenia too late disease that also becomes a complexion changed that makes us talking, keep away.
The treatment schizophrenia drug is since early 1950s is found the antipsycholic action of chlorpromazine, and schizophrenia is always based on Drug therapy.Antipsychotic drug commonly used at present is divided into typical case and atypia two big classes by receptor blocking effect difference: typical psychosis is representative with chlorpromazine, haloperidol. the main mechanism of action is the blocking-up dopamine receptor, (hallucination, vain hope, excited restless, impulsive behavior etc.) have better curative effect to the schizoid positive symptom for they. and The extrapyramidal symptoms (EPS) is common simultaneously, and to negative symptoms (apathy, the poverty of thought, hypobulia etc.) weak curative effect; The anti-smart medicine that divides of atypia, the treatment spectrum is wider, the negative symptoms effect obviously is better than conventional medicament, safe, side effect is slighter, and taking dose is littler, a lot of more advanced dosage forms also occurred, greatly improve patient's compliance, represented medicine that clozapine, risperidone, olanzapine, cis-N-[4-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl etc. are arranged.
Blonanserin is 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-six hydrogen cycloocta-[b] pyridines are atypia antischizophrinic things of new generation, are that European patent EP 0385237 is open the earliest, illustrated its superior medical treatment public tender that, disclose it and be used for the treatment of schizophrenia.The domestic no import of this product does not at present have the said preparation of production yet.The Spain and the U.S. are in the II clinical trial phase.2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9, the blonanserin general by name (Blonanserin) of 10-six hydrogen cycloocta-[b] pyridines, molecular formula: C
23H
30FN
3, molecular weight: 367.5, its structural formula is as follows:
It belongs to the medicine of the single-minded 5-HT2 of acting on receptor and D2 receptor, is the medicine that approaches selectively acting in the present atypical antipsychotic market most.Obviously improve schizoid positive shape (as hallucination, illusion etc.) and negative symptoms (as feel down in spirits, hypokinesia etc.), reduce extrapyramidal system rate of side effects (parkinson's syndrome, acute dystonia, cathisophobia etc.) and other untoward reaction, the safety toleration obviously is better than traditional antipsychotic drug.Appearance that we can say it is the much progress on the schizophrenia drug treatment history.As the schizoid line medication of treatment. will have broad application prospects in China.
Therefore be necessary to prepare a kind of being easy to carry, the oral formulations of taking convenience fills the domestic gaps.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of 2-of containing (4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9, oral formulations of 10-six hydrogen cycloocta-[b] pyridines and preparation method thereof.
The invention provides the schizoid 2-of containing of a kind of treatment (4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9, the oral formulations of 10-six hydrogen cycloocta-[b] pyridines, said preparation contain 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5 of 0.1-30wt%, 6,7,8,9,10-six hydrogen cycloocta-[b] pyridines, said preparation has good moistening, disintegrating property can discharge medicine fast and fully, gives full play to the therapeutical effect of active component, on the other hand, the present invention also provides 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9, the preparation method of the oral formulations of 10-six hydrogen cycloocta-[b] pyridines, said preparation is applicable to that the patient takes l-2 time every day, each 1-2 preparation unit is with treatment schizophrenia.
" oral formulations " is meant disintegrate fully in gastrointestinal, and the preparation of release of active ingredients, said preparation are suitable for the patient to be taken 1-2 time easily every day, and each 1-2 preparation unit is with treatment schizophrenia.
Oral formulations of the present invention, it comprises 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9, the immixture of certain character that 10-six hydrogen cycloocta-[b] pyridines and suitable medicinal inert excipient are made, as compressed tablet or granule, also can be in the outer gastric solubility coatings that covers of immixture with the outward appearance of improving preparation and stability etc., oral formulations of the present invention be meant active component in simulated gastric fluid in (common in vitro tests is the hydrochloric acid solution of preparation at 0.1mol/L) 30 minutes disintegrate discharge and be no less than 70%, promptly show to discharge fully.Table 1 has been summarized the solubility property (with reference to Chinese Pharmacopoeia 2000 year version) of blonanserin under different pH value
Table 1 has been summarized the solubility property of blonanserin under different pH value
For active component disintegrate in human body is discharged fully, be necessary to select one or more inert excipients, this excipient can guarantee that the active component disintegrate discharges fully, can meet China's industrialized great production reality again, production technology is simple.If active agent preparation is stripping and being absorbed fully in human body, make that the activity component concentration in the individual blood plasma is widely different, be not easy to treatment, and unforeseeable untoward reaction might take place.
Therefore the schizoid oral formulations of treatment of the present invention comprises 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5 of 0.1-30wt%, 6,7,8,9,10-six hydrogen cycloocta-[b] pyridines and one or more pharmaceutically acceptable inert excipients, described oral formulations comprises tablet, capsule, granule; Described inert excipient comprises diluent, binding agent, disintegrating agent, antitack agent and lubricant; Described diluent be selected from lactose, microcrystalline Cellulose, pregelatinized Starch and starch, and composition thereof; Described binding agent be selected from sodium carboxymethyl cellulose, hyetellose, hyprolose, hydroxypropyl emthylcellulose, sodium alginate, methylcellulose, gelatin, polyvinylpyrrolidone, cellulose acetate, starch pregelatinized Starch, and composition thereof; Described disintegrating agent be selected from sodium carboxymethyl cellulose, microcrystalline Cellulose, cellulose powder, cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, alginic acid, sodium alginate, pregelatinized Starch, starch, and composition thereof; Described antitack agent be selected from silicon dioxide, micropowder silica gel, magnesium trisilicate and Pulvis Talci, and composition thereof; Described lubricant be selected from magnesium stearate, Pulvis Talci, and composition thereof, described wetting agent is aqueous solution, ethanol water.
Contain in the oral formulations of the present invention: 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-six hydrogen cycloocta-[b] pyridine 0.1-30wt%, diluent 1-96wt%; Binding agent 2-20wt%; Disintegrating agent 0.5-15wt%; Antitack agent 0-5wt%; Lubricant 0.2-5wt%.
Oral formulations preferred ingredient of the present invention is formed: 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-six hydrogen cycloocta-[b] pyridine 0.2-25wt%, diluent 5-95wt%; Binding agent 4-18wt%; Disintegrating agent 2-8wt%; Antitack agent 0.3-4wt%; Lubricant 0.5-3wt%.
2-(4-ethyl-1-the piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9 that contains 2-16mg in the preparation of oral formulations of the present invention, 10-six hydrogen cycloocta-[b] pyridines are suitable for the patient and take 1-2 time every day, each 1-2 preparation unit.
Preferable absorbent is the mixture of pregelatinized Starch, lactose and microcrystalline Cellulose in the oral formulations of the present invention; Disintegrating agent is a cross-linking sodium carboxymethyl cellulose, and binding agent is a hydroxypropyl emthylcellulose, and antitack agent is micropowder silica gel, and lubricant is a magnesium stearate.
Also can be in the outer gastric solubility coatings that covers of preparation of the present invention to improve the outward appearance of preparation, the sense of taste and stability etc., the coating weightening finish is 0.1-20% with the weight ratio of compressed tablet, preferred 0.5-18%, the best is 1.0-15%, being made up of following component of particularly preferred oral formulations of the present invention:
Wherein the concentration of alcohol in the ethanol water is 5-95wt%, preferred 20-75wt%.
The oral formulations of treatment schizophrenia of the present invention prepares as follows:
1) compressed tablet: active component and selectable diluent, binding agent and disintegrating agent are put in the mixer; add an amount of wetting agent and make soft material; soft material pressed suitable screen cloth to make granule; it is dry immediately; granulate sieves; with antitack agent and lubricant and the dried granule mix homogeneously of gained, tabletting promptly gets label.Circular sheet character of the present invention, preferred method of granulating are to stir to granulate or the airpillow-dry granulation.
2) capsule: active component and selectable excipient are put in the mixer, added an amount of wetting agent and make soft material, soft material pressed suitable screen cloth to make granule; it is dry immediately; the granulate that sieves is with antitack agent and lubricant and the dried granule mix homogeneously of gained, in the snap fit capsule of packing into.
3) granule: active component and selectable excipient and correctives are put in the mixer, added an amount of wetting agent and make soft material, soft material pressed suitable screen cloth to make granule, and it is dry immediately, and the granulate that sieves is divided in the medicinal compound membrane bag.
The advantage of above-mentioned preparation method is: the wetting agent of use is an ethanol water, and consumption is few, and preparation technology is simple, is suitable for domestic production technology and equipment condition.
The advantage of preparation of the present invention is:
Pharmaceutical preparation of the present invention is stable, and dissolubility is good in water, is convenient to preserve, transport, carry and clinical practice, and is clinical safe in utilization effective.
Preparation technology of the present invention is simple, is suitable for domestic production technology and equipment condition.
Therefore the present invention is favourable for enterprise and patient.
The specific embodiment
Below in conjunction with embodiment the present invention is described in further detail, but should understands the non-scope that only limits to these embodiment of scope of the present invention.
Embodiment 1
Active component is the composition and the preparation method of 2mg compressed tablet
With active component 2.0g, microcrystalline Cellulose 20.0g, pregelatinized Starch 15.0g, lactose 36.0g, cross-linking sodium carboxymethyl cellulose 6.0g, hydroxypropyl emthylcellulose 4.0g, mix homogeneously, with the 50wt% ethanol water is wetting agent system soft material, 30 eye mesh screens are granulated, 55 ℃ of aeration-dryings, granulate, add micropowder silica gel 0.5g mixing, press about 1000 round, every contains active component 2mg, promptly gets compressed tablet.
Embodiment 2
Active component is the composition and the preparation method of 4mg compressed tablet
With active component 4.0g, microcrystalline Cellulose 40.0g, pregelatinized Starch 20.0g, lactose 66.0g, cross-linking sodium carboxymethyl cellulose 8.0g, hydroxypropyl emthylcellulose 8.0g, mix homogeneously, with the 50wt% ethanol water is wetting agent system soft material, 30 eye mesh screens are granulated, 55 ℃ of aeration-dryings, granulate, add magnesium stearate 1g and micropowder silica gel 1g mixing, press about 1000 round, every contains active component 4mg, promptly gets compressed tablet.
Embodiment 3
Active component is the composition and the preparation method of 8mg compressed tablet
With active component 8.0g, microcrystalline Cellulose 60.0g, pregelatinized Starch 30.0g, lactose 100.0g, cross-linking sodium carboxymethyl cellulose 12.0g, mix homogeneously, with 3wt% hydroxypropyl emthylcellulose aqueous solution is wetting agent system soft material, 30 eye mesh screens are granulated, 55 ℃ of aeration-dryings, granulate adds magnesium stearate 2g and micropowder silica gel 1g mixing, press about 1000 round, every contains active component 8mg, promptly gets compressed tablet.
Embodiment 4
Active component is capsular composition of 4mg and preparation method
With active component 4.0g, microcrystalline Cellulose 15.0g, pregelatinized Starch 15.0g, lactose 36.0g, cross-linking sodium carboxymethyl cellulose 4.0g, insert in the quick mixer granulator; spraying the 40wt% ethanol water is wetting agent system soft material; 40 eye mesh screens are granulated; 55 ℃ of aeration-dryings; granulate; add magnesium stearate 0.5g and micropowder silica gel 0.5g mixing, No. 4 bright hard capsules of fill make every capsules contain active component 4mg.
Embodiment 5
Active component is film-coated composition of 4mg and preparation method
With active component 4.0g, microcrystalline Cellulose 40.0g, pregelatinized Starch 20.0g, lactose 66.0g, cross-linking sodium carboxymethyl cellulose 8.0g, hydroxypropyl emthylcellulose 8.0g, mix homogeneously, with the 50wt% ethanol water is wetting agent system soft material, 30 eye mesh screens are granulated, 55 ℃ of aeration-dryings, granulate, add magnesium stearate 1g and micropowder silica gel 1g mixing tabletting, compressed tablet bag OPADAY film, every contains active component 4mg, promptly gets Film coated tablets.
Embodiment 6
Active component is capsular composition of 16mg and preparation method
With active component 16.0g, microcrystalline Cellulose 25.0g, pregelatinized Starch 25.0g, lactose 72.0g, cross-linking sodium carboxymethyl cellulose 10.0g, insert in the quick mixer granulator; spraying the 30wt% ethanol water is wetting agent system soft material; 40 eye mesh screens are granulated; 55 ℃ of aeration-dryings; granulate; add magnesium stearate 1g and micropowder silica gel 1g mixing, No. 2 bright hard capsules of fill make every capsules contain active component 16mg.
Embodiment 7
Active component is particulate composition of 8mg and preparation method
With active component 8.0g, first class cellulose 50.0g, pregelatinized Starch 150.0g, lactose 150.0g, gelatin 10.0g, aspartame 0.05g, cross-linking sodium carboxymethyl cellulose 12.0g, mix homogeneously, with 3wt% hydroxypropyl emthylcellulose aqueous solution is wetting agent system soft material, 18 eye mesh screens are granulated, 55 ℃ of aeration-dryings, granulate, be divided in the PVC clad aluminum foil bag, make every bag to contain active component 8mg, promptly.
Embodiment 8
The preparation that external comparing embodiment 1-4 makes
Present embodiment is described not coated preparation that embodiment of the invention 1-4 the makes accordingly result according to relevant dissolution determination method test in two appendix of Chinese Pharmacopoeia version in 2005 in detail.
Dissolution: shine dissolution method (two appendix XC second methods of Chinese Pharmacopoeia version in 2005) with 900ml, 0.1mol/L hydrochloric acid solution is a dissolution medium, rotating speed is that per minute 50 changes, operation in accordance with the law, in the time of 30 minutes, it is an amount of to get solution, filters, subsequent filtrate 10ml measures, and table has been summed up the dissolution data of the prepared blonanserin preparation of embodiment of the invention 1-4.
The external stripping contrast of table embodiment 1-4
Last watch test data show, press embodiment 1-4 45 minutes basic releases fully in acid that the technology of the present invention is implemented, i.e. release is no less than 80%.
Claims (4)
1. treat schizoid 2-(4-ethyl-1-the piperazinyl)-4-(4-fluorophenyl)-5,6,7 that contains for one kind, 8,9, the oral formulations of 10-six hydrogen cycloocta-[b] pyridines is characterized in that: said preparation comprises 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-six hydrogen cycloocta-[b] pyridines and one or more pharmaceutically acceptable inert excipients, described oral formulations comprises tablet, capsule, granule; Described inert excipient comprises diluent, binding agent, disintegrating agent, antitack agent and lubricant; Contain in the preparation: 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-six hydrogen cycloocta-[b] pyridine 0.1-30wt%, diluent 1-96wt%; Binding agent 2-20wt%; Disintegrating agent 0.5-15wt%; Antitack agent 0-5wt%; Lubricant 0.2-5wt%; Described diluent be selected from lactose, microcrystalline Cellulose, pregelatinized Starch and starch, and composition thereof; Described binding agent be selected from sodium carboxymethyl cellulose, hyetellose, hyprolose, hydroxypropyl emthylcellulose, sodium alginate, methylcellulose, gelatin, polyvinylpyrrolidone, cellulose acetate, starch pregelatinized Starch, and composition thereof; Described disintegrating agent be selected from sodium carboxymethyl cellulose, microcrystalline Cellulose, cellulose powder, cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, alginic acid, sodium alginate, pregelatinized Starch, starch, and composition thereof; Described antitack agent be selected from silicon dioxide, micropowder silica gel, magnesium trisilicate and Pulvis Talci, and composition thereof; Described lubricant be selected from magnesium stearate, Pulvis Talci, and composition thereof, described wetting agent is aqueous solution, ethanol water.
2. oral formulations as claimed in claim 1 is characterized in that containing in the preparation: 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-six hydrogen cycloocta-[b] pyridine 0.2-25wt%, diluent 5-95wt%; Binding agent 4-18wt%; Disintegrating agent 2-8wt%; Antitack agent 0.3-4wt%; Lubricant 0.5-3wt%.
3. as the described oral formulations of claim 1-2, it is characterized in that containing in the preparation 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6 of 2-16mg, 7,8,9,10-six hydrogen cycloocta-[b] pyridines are suitable for the patient and take 1-2 time every day, each 1-2 preparation unit.
4. oral formulations as claimed in claim 1 is characterized in that its diluent is the mixture of pregelatinized Starch, lactose and microcrystalline Cellulose; Disintegrating agent is a cross-linking sodium carboxymethyl cellulose, and binding agent is a hydroxypropyl emthylcellulose, and antitack agent is micropowder silica gel, and lubricant is a magnesium stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810154638 CN101766626B (en) | 2008-12-30 | 2008-12-30 | Blonanserin-contained oral preparation for treating schizophrenia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810154638 CN101766626B (en) | 2008-12-30 | 2008-12-30 | Blonanserin-contained oral preparation for treating schizophrenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101766626A true CN101766626A (en) | 2010-07-07 |
| CN101766626B CN101766626B (en) | 2012-03-07 |
Family
ID=42499827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810154638 Active CN101766626B (en) | 2008-12-30 | 2008-12-30 | Blonanserin-contained oral preparation for treating schizophrenia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101766626B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102038685A (en) * | 2010-11-29 | 2011-05-04 | 天津市汉康医药生物技术有限公司 | Blonanserin medicine composition with capacity of improving oral absorbability |
| CN102078321A (en) * | 2010-12-31 | 2011-06-01 | 泰州万全医药科技有限公司 | Blonanserin-containing medicinal composition and preparation method thereof |
| CN102240270A (en) * | 2010-05-13 | 2011-11-16 | 丽珠医药集团股份有限公司 | Blonanserin tablet and preparation method thereof |
| CN102274162A (en) * | 2011-08-02 | 2011-12-14 | 无锡万全医药技术有限公司 | Solid composition comprising insoluble medicine and hydrophilic gel material and preparation method thereof |
| CN102727453A (en) * | 2011-04-01 | 2012-10-17 | 北京德众万全医药科技有限公司 | Blonanserin dispersible tablet and its preparation method |
| CN102949392A (en) * | 2012-11-27 | 2013-03-06 | 西安泰科迈医药科技有限公司 | Medicinal composition for treating schizophrenia and preparation method thereof |
| US20130143897A1 (en) * | 2010-08-10 | 2013-06-06 | Lupin Limited | Oral controlled release pharmaceutical compositions of blonanserin |
| CN107080739A (en) * | 2017-04-17 | 2017-08-22 | 深圳市泛谷药业股份有限公司 | A kind of solid quick release blonanserin piece for being used to be administered orally and preparation method thereof |
| JP2018203706A (en) * | 2017-06-08 | 2018-12-27 | 高田製薬株式会社 | Tablet containing blonanserin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0385237B1 (en) * | 1989-03-03 | 1994-06-29 | Dainippon Pharmaceutical Co., Ltd. | 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same |
| US8354121B2 (en) * | 2006-06-09 | 2013-01-15 | Dainippon Sumitomo Pharma Co., Ltd. | Tape preparation |
| CN101530412A (en) * | 2008-03-10 | 2009-09-16 | 北京德众万全医药科技有限公司 | Pharmaceutical composition of blonanserin and preparation method thereof |
-
2008
- 2008-12-30 CN CN 200810154638 patent/CN101766626B/en active Active
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102240270A (en) * | 2010-05-13 | 2011-11-16 | 丽珠医药集团股份有限公司 | Blonanserin tablet and preparation method thereof |
| CN102240270B (en) * | 2010-05-13 | 2013-01-02 | 丽珠医药集团股份有限公司 | Blonanserin tablet and preparation method thereof |
| US20130143897A1 (en) * | 2010-08-10 | 2013-06-06 | Lupin Limited | Oral controlled release pharmaceutical compositions of blonanserin |
| CN102038685A (en) * | 2010-11-29 | 2011-05-04 | 天津市汉康医药生物技术有限公司 | Blonanserin medicine composition with capacity of improving oral absorbability |
| CN102078321A (en) * | 2010-12-31 | 2011-06-01 | 泰州万全医药科技有限公司 | Blonanserin-containing medicinal composition and preparation method thereof |
| CN102727453A (en) * | 2011-04-01 | 2012-10-17 | 北京德众万全医药科技有限公司 | Blonanserin dispersible tablet and its preparation method |
| CN102274162A (en) * | 2011-08-02 | 2011-12-14 | 无锡万全医药技术有限公司 | Solid composition comprising insoluble medicine and hydrophilic gel material and preparation method thereof |
| CN102949392A (en) * | 2012-11-27 | 2013-03-06 | 西安泰科迈医药科技有限公司 | Medicinal composition for treating schizophrenia and preparation method thereof |
| CN107080739A (en) * | 2017-04-17 | 2017-08-22 | 深圳市泛谷药业股份有限公司 | A kind of solid quick release blonanserin piece for being used to be administered orally and preparation method thereof |
| JP2018203706A (en) * | 2017-06-08 | 2018-12-27 | 高田製薬株式会社 | Tablet containing blonanserin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101766626B (en) | 2012-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101766626B (en) | Blonanserin-contained oral preparation for treating schizophrenia | |
| EP1781260B1 (en) | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof | |
| CN102657629B (en) | Ticagrelor sustained-release tablet system and preparation method thereof | |
| CN113925838B (en) | Compound sustained-release tablet of epalrestat and sitagliptin or pharmaceutically acceptable salt thereof and preparation method thereof | |
| CN110898025A (en) | Acarbose sustained-release preparation and preparation method thereof | |
| CN104173312A (en) | Sustained-release tablet containing felodipine and metoprolol salt and preparation method of sustained-release tablet containing felodipine and metoprolol salt | |
| CN103520128A (en) | Pramipexole sustained-release tablet, preparation method and application thereof | |
| CN113018273A (en) | Solid preparation and preparation method and application thereof | |
| JP6027710B1 (en) | Solid preparation for diabetes treatment | |
| US20220288056A1 (en) | Pharmaceutical composition containing nitroxoline, nitroxoline oral solid tablet, preparation method therefor and use thereof | |
| CN103006594A (en) | Glimepiride composite and preparation method thereof | |
| CN111202731B (en) | Combined application, medicinal composition and application thereof | |
| CN111557920A (en) | Lipoic acid-containing tablet and preparation method thereof | |
| CN109157527B (en) | Irbesartan capsule and preparation method thereof | |
| CN102727894A (en) | Pharmaceutical composition for treating diabetes and its complications and application thereof | |
| CN107028903A (en) | Blonanserin tablet pharmaceutical composition and preparation method thereof | |
| CN113018271B (en) | Tandospirone pharmaceutical composition and preparation method and application thereof | |
| CN114533744A (en) | Ticagrelor-aspirin compound pellet preparation and preparation method thereof | |
| CN101244068B (en) | Hemsleyadin sustained-release preparation | |
| CN111544409B (en) | Pharmaceutical composition of metformin hydrochloride and mecobalamin and preparation method thereof | |
| WO2022036506A1 (en) | Composition and use of sglt-2 inhibitor and angiotensin receptor blockers | |
| WO2023173460A1 (en) | Pharmaceutical composition of sglt-2 inhibitor | |
| CN104337783B (en) | A kind of capecitabine tablet and preparation method thereof | |
| CN104739795A (en) | Glipizide sustained release tablet and preparation method thereof | |
| CN117442573A (en) | Eszopiclone pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LIZHU MEDICINE GROUP CO., LTD. Free format text: FORMER OWNER: YAN JIE Effective date: 20110909 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300203 HEXI, TIANJIN TO: 519020 ZHUHAI, GUANGDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110909 Address after: 519020 No. 132, Guihua North Road, Zhuhai, Guangdong, Gongbei Applicant after: Lizhu Medicine Group Co., Ltd. Address before: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Applicant before: Yan Jie |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |